China is the country it is impossible to ignore and now accounts for a significant share of revenues for most major multinational pharmaceutical companies. Further, any firm sincerely committed to bringing treatments to the greatest number of patients has to be active in China, whose population of 1.3 billion people makes up nearly a fifth of the world’s total.

This report examines the welter of healthcare reforms that have been rolled out over the past decade and the significant changes yet to come. It also looks at the biotech boom taking off in the country and the swathe of major MNC talent returning to China to be a part of it.